Bridging gaps across the CLL care pathway – Part 1: From Signal to Stratification
By Léon Van Wouwe, Clinical Innovation Director, Volv Global From Signal to Stratification – Reimagining Early CLL Care through Algorithmic
By Léon Van Wouwe, Clinical Innovation Director, Volv Global From Signal to Stratification – Reimagining Early CLL Care through Algorithmic
By Léon Van Wouwe, Clinical Innovation Director, Volv Global A Hidden Cancer in Plain Sight Multiple myeloma (MM) has
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: The Urgency of Early Diagnosis in Type 1 Diabetes
How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: A case study in alpha-1 antitrypsin deficiency
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Recently, I had powerful thought come to me on reading
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Emerging artificial intelligence solutions offer promising strategies to address critical
By Léon Van Wouwe, Clinical Innovation Director, Volv Global New data from Roche’s Itovebi (inavolisib) combined with Pfizer’s Ibrance
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Progressive Pulmonary Fibrosis (PPF) is a severe clinical condition
Alpha-1 antitrypsin deficiency (AATD), a rare genetic condition, can cause lung disease in adults with symptoms similar to chronic obstructive
By Christopher Rudolf, Volv Global An AI Methodology for Finding Patients with Rare Diseases: Volv Global’s inTrigue Finding patients with
